Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

• Published in: Cell Vol. 186; no. 12; pp. 2628 - 2643.e21
• Main Authors: Arora, Mansi, Moser, Justin, Hoffman, Timothy E., Watts, Lotte P., Min, Mingwei, Musteanu, Monica, Rong, Yao, Ill, C. Ryland, Nangia, Varuna, Schneider, Jordan, Sanclemente, Manuel, Lapek, John, Nguyen, Lisa, Niessen, Sherry, Dann, Stephen, VanArsdale, Todd, Barbacid, Mariano, Miller, Nichol, Spencer, Sabrina L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.06.2023
• Subjects: CDK plasticity; CDK2; CDK4/6; cyclin A; drug adaptation; Palbociclib; PF-06873600; PF-07104091; restriction point; Rb; CDK4/6; PF-06873600; restriction point; drug adaptation; CDK plasticity; CDK2; Palbociclib; cyclin A; PF-07104091

CDK2 is a core cell-cycle kinase that phosphorylates many substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, we use several CDK2 inhibitors in clinical development to interrogate CDK2 substrate p...